1 3 1, , , ,115. February 16, 2017 Consolidated Balance Sheet, Years Ended Dec. 31 ($000): 2017

Transcription

1 MERGENT OTC UNLISTED NEWS REPORTS Tuesday, March 20, 2018 Volume 34 No. 3 NAME CHANGES (For details on individual listings, see the News Section of this issue) ATI Modular Technology Corp (to AmericaTowne Holdings Inc) Emerald Medical Applications Corp (to Virtual Crypto Technologies Inc) Snap Interactive Inc (to PeerStream Inc) Vican Resources Inc (to Frelii Inc) 3POWER ENERGY GROUP INC Earnings, 9 mos. to Dec 31(Consol. $): Cost & expenses , ,162 Operating income (492,769) (424,167) Interest expense , ,194 (expense), net , Gains or losses ,523,180 39,470 Net before taxes ,130,608 (524,891) Net income ,130,608 (524,891) Earnings common share Common Shares: Full Diluted ,295, ,949,923 Year-end ,295, ,949,923 AAON, INC. Consolidated Income Statement, Years Ended Dec. 31 ($000): 2015 Net sales , , ,632 Cost of sales , , ,951 Gross profit , , ,681 Selling, general & expenses ,249 38,506 37,438 Gain (loss) on disposal of assets.... (45) operations ,103 79,594 71,302 Interest income (expense), net (expense), net (124) before taxes ,492 79,991 71,339 Current income tax provision (benefit)... 21,548 25,790 24,439 Deferred income tax provision (benefit)... (1,554) 825 1,172 Income tax provision ,994 26,615 25, ,498 53,376 45,728 - basic ,572 52,924 54,046 - diluted ,079 53,450 54,481 outstanding ,423 52,651 53,012 per share - basic..... $1.04 $1.01 $0.85 per share - diluted.... $1.03 $1.00 $0.84 Cash dividends declared per common share $0.26 $0.24 $0.22 NOTICE Items in this issue will be listed online weekly and printed monthly , , , , , ,120 1 As is; 2 As of February 12, 2018; 3 As of February 12, ; 4 As of February 19, 2016; 5 As of February 23, 2018; 6 As of February 16, Consolidated Balance Sheet, Years Ended Dec. 31 ($000): Cash & cash equivalents ,457 24,153 Certificates of deposit ,880 5,512 Investments held to maturity at amortized cost ,077 14,083 Accounts receivable ,457 43,091 Less: allowance for doubtful accounts Accounts receivable, net ,338 43,001 Income tax receivable ,643 6,239 Notes receivable Raw materials ,784 43,438 Work in process ,957 2,279 Finished goods ,163 3,017 Inventories, gross ,904 48,734 Less: allowance for excess & obsolete inventories ,118 1,382 Inventories, net ,786 47,352 current assets Total current assets , ,981 Land ,233 2,233 Buildings ,075 78,806 Machinery & equipment , ,216 Furniture & fixtures ,714 12,783 Total property, plant & equipment , ,038 depreciation , ,146 Property, plant & equipment, net , ,892 Note receivable, long-term Total assets , ,530 Accounts payable ,967 7,102 Accrued warranty ,483 7,936 Accrued due to representatives ,086 9,907 Accrued payroll ,456 4,129 Accrued profit sharing ,034 1,967 Accrued workers compensation Accrued medical self-insurance Accrued customer prepayments ,838 2,256 Accrued donations Accrued employee vacation time ,688 2,367 Other accrued liabilities ,607 1,326 Accrued liabilities ,098 31,940 Total current liabilities ,065 39,042 Deferred revenue ,512 1,498 Deferred tax liabilities ,977 9,531 Donations Common stock (accumulated deficit) , ,687 equity , ,898 1 Reclassified to conform with presentation 1. AAON, Inc. common. 1. AAON, Inc. common. ACCELERATE DIAGNOSTICS INC Net sales ,177, , ,000 Cost of sales ,002, Gross profit (loss).... 3,175, , ,000 development ,301,000 29,564,000 27,142,000 Sales, general & expenses ,058,000 37,183,000 18,554,000 Total costs & expenses ,359,000 66,747,000 45,696,000 operations (64,184,000) (66,501,000) (45,549,000) Interest expense ,000 Foreign currency exchange loss (75,000) (77,000) (19,000) Interest & dividend income , ,000 74,000 Other expense, net ,000 23, (expense), net , ,000 51,000 before income taxes.. (63,535,000) (66,107,000) (45,498,000) Current foreign income taxes , , Current income taxes , , Provision for income taxes , , (64,028,000) (66,374,000) (45,498,000) - basic ,073,000 51,276,000 44,998,000 - diluted ,073,000 51,276,000 44,998,000 outstanding ,673,810 51,516,309 51,191,184 per share - basic..... $(1.18) $(1.29) $(1.01) per share - diluted.... $(1.18) $(1.29) $(1.01) Foreign currency translation adjustments (128,000) 1,000 1 Reclassified to conform with presentation; 2 Approximately; 3 As of February 23, 2018; 4 As of February 25, ; 5

2 218 MERGENT OTC UNLISTED NEWS March 20, 2018 As of March 8, 2016 Cash & cash equivalents ,513,000 19,244,000 Investments ,648,000 58,519,000 Trade accounts receivable ,946,000 34,000 Inventory ,063, Prepaid expenses , ,000 Other current assets , ,000 Total current assets ,488,000 78,448,000 Computer equipment ,756,000 2,270,000 Technical equipment ,348,000 2,427,000 Facilities ,621,000 3,387,000 Instruments ,400, Capital projects in progress ,000 1,010,000 Total property & equipment ,474,000 9,094,000 Accumulated depreciation - other ,584,000 4,836,000 net ,890,000 4,258,000 Intellectual property, net , ,000 Total assets ,512,000 82,852,000 Accounts payable ,080, ,000 Accrued liabilities ,636,000 3,009,000 Deferred revenue & income ,071,000 35,000 Total current liabilities ,787,000 4,036,000 Long-term deferred income ,000,000 Other long-term liabilities , Total liabilities ,808,000 5,036,000 Common stock ,000 52,000 Contributed capital ,620, ,257,000 (accumulated deficit) (241,972,000) (177,289,000) (loss) (204,000) Total shareholders equity (deficit) ,704,000 77,816, Accelerate Diagnostics Inc common. 1. Accelerate Diagnostics Inc common. ACHIEVE LIFE SCIENCE INC Collaboration revenue ,062,000 18,160,000 development ,101,000 14,788,000 25,108, ,531,000 8,933,000 11,805,000 Restructuring costs (recovery) ,206, Recovery of lease termination loss (1,250,000)... Litigation settlement ,375, Asset impairment charge , expenses ,632,000 26,254,000 36,913,000 Interest income , , ,000 (expense) (35,000) (13,000) (64,000) Bargain purchase gain ,272, Contingent value rights recovery , Gain (loss) on warrants , ,000 1,897,000 Gains (losses) on disposition of intangible asset (8,610,000) (expense) (7,002,000) 1,063,000 1,952,000 for the period before taxes (13,634,000) Income tax expense (recovery) (3,051,000) (10,583,000) (20,129,000) (16,801,000) - basic ,794, ,722,676 2,377,031 - diluted ,794, ,722,676 2,377,031 outstanding ,947, ,729,593 2,710,273 per share - basic..... $(2.21) 3 $(7.37) $(7.04) per share - diluted.... $(2.21) 3 $(7.37) $(7.04) Number of beneficiary 4 5 8, , ,436 Investment tax credit , ,000 & prior financials for the company prior to reverse merger to OncoGenex Pharmaceuticals, Inc; 2 Reclassified to conform with 2016 presentation; 3 Adjusted for 1-for-11 stock split, August 3, ; 4 Approximately; 5 As of February 15, 2018; 6 As of February 15, ; 7 As of February 15, 2016 Cash & cash equivalents ,284,000 15,233,000 Restricted cash , Short-term investments ,230,000 Interest receivable ,000 Amounts receivable , ,000 Prepaid expenses , ,000 Total current assets ,908,000 26,927,000 Restricted cash , ,000 Computer equipment, cost , ,000 depreciation - computer equipment , ,000 Furniture & fixtures, cost , ,000 depreciation - furniture & fixtures , ,000 Leasehold improvements, cost , ,000 depreciation - leasehold improvements , ,000 Computer software, cost , ,000 depreciation - computer software , ,000 Equipment under capital lease, cost , ,000 depreciation - equipment under capital lease , ,000 cost ,144,000 1,707,000 depreciation ,085,000 1,449,000 net , ,000 Other assets ,000 13,000 Licenses, gross ,117, Less: Accumulated amortization - licenses , License agreement ,532, Goodwill ,034, Total assets ,892,000 27,470,000 Accounts payable ,000 2,121,000 Accrued liabilities & other current liabilities ,000 2,442,000 Accrued clinical liabilities ,000 3,415,000 Accrued compensation , ,000 Current portion of long-term obligations ,000 57,000 Warrant liability ,000 Total current liabilities ,013,000 8,455,000 Long-term obligation, less current portion ,000 Total liabilities ,013,000 8,504,000 Common shares ,000 29,000 capital ,556, ,239,000 (accumulated deficit) (12,694,000) (196,942,000) (loss) ,000 2,640,000 Total shareholders equity (deficiency) ,879,000 18,966,000 & prior financials for the company prior to reverse merger to OncoGenex Pharmaceuticals, Inc 1. Achieve Life Science Inc common. 1. Achieve Life Science Inc common. ACRO BIOMEDICAL CO LTD Consolidated Income Statement, Years Ended Sept. 30 ($): 2015 Revenues , Cost of revenues , Gross profit , Selling, general & ,055 3,192 Professional fees ,382 42,373 44,298 expenses ,248 43,428 47,490 before provision for income taxes..... (2,248) (43,428) (2,248) (43,428) (47,490) - basic ,173, ,160,000 43,435,197 - diluted ,173, ,160,000 43,435,197 outstanding ,660, ,160,000 47,160,000 Earnings (loss) per share - basic $ $0.00 $0.00 Earnings (loss) per share - diluted $ $0.00 $0.00 Number of part time Reclassified to conform with presentation; 2 Adjusted for 3-for-1 stock split, May 22, ; 3 As of January 12, 2018; 4 As of December 14, 2016 Consolidated Balance Sheet, Years Ended Sept. 30 ($): Cash & cash equivalents ,810 2,533 Prepaid inventory , Prepaid expenses , Total current assets ,310 2,533 Total assets ,310 2,533 Accounts payable & accrued expenses ,326 Due to related parties ,379 10,000

3 March 20, 2018 MERGENT OTC UNLISTED NEWS 219 Total current liabilities ,979 17,326 Total liabilities ,979 17,326 Common stock ,660 47,160 Additional paid in capital ,912 30,040 (accumulated deficit) (94,241) (91,993) equity (deficit) ,331 (14,793) 1 Reclassified to conform with presentation 1. Acro Biomedical Co Ltd common. 1. Acro Biomedical Co Ltd common. ACRO BIOMEDICAL CO LTD Auditor s Report Auditor s Report The following is an excerpt from the Report of the Independent Auditors, MaloneBailey, LLP, as it appeared in the 10K report: "In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Acro Biomedical Co., Ltd. (formerly known as Killer Waves Hawaii, Inc.) as of September 30, and 2016 and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has suffered recurring losses from operations and has negative operating cash flows that raises substantial doubt about its ability to continue as a going concern. Management s plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty." ADAIAH DISTRIBUTION INC Consolidated Income Statement, Years Ended Oct. 31 ($): Merchandise sales ,509 41, ,839 Total income ,509 41, ,839 Pillow purchases ,613 35,526 89,727 Total cost of goods sold ,613 35,526 89,727 Gross profit (loss).... 6,896 6,104 16, ,031 9,132 63,896 Total expenses ,031 9,132 63,896 before income tax (1,134) (3,028) (47,784) Provision (benefit) for income tax (3,894)... for period (1,134) 866 (47,784) - basic , , ,000 - diluted , , ,000 outstanding , , ,000 Net income gain (loss) per share - basic $ $ $(0.40) Net income gain (loss) per share - diluted $ $ $(0.40) Other number of Number of part time Reclassified to conform with the 2016 presentation; 2 As reported by Company; 3 Adjusted for 1-for-1,000 stock split, November 8, 2016; 4 Adjusted for 25-for-1 stock split, December 18, 2015 Consolidated Balance Sheet, Years Ended Oct. 31 ($): Cash Total current assets Furniture & equipment ,000 8,000 depreciation - furniture & equipment ,571 2,143 Sewing shop ,940 16,940 depreciation - sewing shop ,329 1,905 Total fixed assets ,040 20,892 Total assets ,073 21,207 Loan payable - related party ,415 1,415 Total liabilities ,415 1,415 Common stock ,000 5,000 capital ,000 39,000 Profit (loss) accumulated during the development stage (25,342) (24,208) equity (deficit) ,658 19, Adaiah Distribution Inc common. 1. Adaiah Distribution Inc common. ADVANTEGO CORP New Accountant On Feb. 5, 2018, Co. dismissed Pritchett, Siler & Hardy, P.C. as its independent public accounting firm. On Feb. 22, 2018, Co. engaged Heaton & Company, PLLC as its new independent public accouting firm. ALL FOR ONE MEDIA CORP Consolidated Income Statement, Years Ended Sept. 30 ($): 2015 Compensation expense , , Professional & consulting expense ,704 1,400, expenses ,459 60,704 52,026 Service & boarding ,323 expenses ,203 2,175,106 54,349 Income loss) from operations (968,203) (2,175,106) (54,349) Derivative expense... 1,773, , Change in fair value of derivative liabilities (1,363,996) 118, Interest income Other expense from loan guarantee , Interest expense ,944 21, Interest expense, related party ,992 (expense) (3,985,729) (108,170)... before provision for income taxes..... (4,953,932) (2,283,276) (61,341) Provision for income taxes (4,953,932) (2,283,276) (61,441) non-controlling interest , All For One Media Corp.. (4,889,704) (2,283,276)... - basic ,465,939 10,367, ,500 - diluted ,465,939 10,367, ,500 outstanding ,235,361 16,509, ,500 Earnings (loss) per share - basic $(0.25) $(0.22) $(0.06) Earnings (loss) per share - diluted $(0.25) $(0.22) $(0.06) Number of As reported from the September 30, 10K; 2 As of January 1, 2018 Consolidated Balance Sheet, Years Ended Sept. 30 ($): Cash & cash equivalents ,785 44,323 current assets ,105 24,380 Total current assets ,890 68,703 Film production costs ,931, Total assets ,220,739 68,703 Accounts payable ,522 8,147 Accrued salaries ,051 15,752 Accrued production related expenses , Accrued rent ,000 2,700 Accrued professional fees ,700 10,000 Accounts payable & accrued liabilities ,273 36,599 Accrued interest , Convertible notes payable, net of debt discounts - current ,915 10,834 Loans payable, net of debt discount ,740, Due to related parties ,701 2,701 Derivative liabilities ,224, ,374 Total current liabilities ,438, ,860 Convertible notes payable including accrued interest, net of debt discounts - long term ,710 10,299 Total liabilities ,671, ,159 Capital stock ,236 16,510 capital ,813,095 2,350,889 (accumulated deficit) (7,470,559) (2,580,855) Total All For One Media Corp. Stockholders deficit (3,632,228) (213,456) Non-controlling interest in subsidiary , equity (deficit) (3,451,026) (213,456) 1 As reported from the September 30, 10K 1. All For One Media Corp common. 1. All For One Media Corp common. ALL FOR ONE MEDIA CORP Auditor s Report Auditor s Report The following is an excerpt from the Report of the Independent Auditors, MaloneBailey, LLP, as it appeared in Co. s 10K report: "In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of All for One Media Corp. and its subsidiaries as of September 30, and 2016, and the consolidated results of their operations and their cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America. The accompanying consolidated

4 220 MERGENT OTC UNLISTED NEWS March 20, 2018 financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raises substantial doubt about its ability to continue as a going concern. Management s plans in regard to these matters are also described in Note 3. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty." AMERICATOWNE HOLDINGS INC New Name On Mar. 8, 2018, Co. changed its name from ATI Modular Technology, Inc. to AmericaTowne Holdings, Inc. AMPLIFY ENERGY CORP Consolidated Income Statement, Years Ended ($000): 1 12/31/ /04/ /31/16 Oil & natural gas sales , , ,051 Other revenues Total revenues , , ,580 Lease operating ,547 35, ,175 Gathering, processing & transportation ,652 10,772 34,979 Exploration Taxes other than income ,101 5,187 15,540 Depreciation, depletion & amortization ,979 37, ,629 Impairment of proved oil & natural gas properties , ,506 31,606 63,280 Accretion of asset retirement obligations ,384 3,407 10,231 Gain (loss) on commodity derivative instruments (31,609) 23,076 (117,105) Gain (loss) on sale of properties ,754 Other costs & expenses, net Total costs & expenses , , ,119 Operating income (loss) (816) 7,963 (436,539) Interest expense, net ,936 10, ,031 (expense) , Gain on extinguishment of debt ,337 (expense) ,045 (10,235) (103,686) before reorganization items, net and income taxes (229) 2, ,225 Reorganization items, net ,119 88, Current income tax expense - federal..... (4)... (6) Current income tax expense - state (17) (8) Total current.. 30 (17) (14) Deferred income tax expense - federal..... (1,933) (71) (8) Deferred income tax expense - state (273) (3) 195 Total deferred.. (2,206) (74) 187 Income tax expense (benefit) (2,176) (91) ,286 (90,995) (540,398) Net income Memorial Production Partners LP , (540,398) successor/predecessor 1,286 (90,955) (540,398) Net (income) loss allocated to predecessor s general partner Net (income) allocated to participating restricted (35) Limited partners interest in net income (loss) ,251 (90,955) (540,230) limited partner units outstanding - basic ,000 83,807 83,351 limited partner units outstanding - diluted ,000 83,807 83,351 Year end partnership units outstanding , ,828 per unit - basic $0.05 $(1.09) $(6.48) per unit - diluted..... $0.05 $(1.09) $(6.48) Cash distributions declared per unit $0.16 unitholders Successor; 2 Predecessor; 3 Reclassified to conform with presentation; 4 As is; 5 Approximately; 6 As of February 28, 2018; 7 As of January 10, Consolidated Balance Sheet, Years Ended Dec. 31 ($000): 1 Cash & cash equivalents ,392 Accounts receivables ,391 Short-term derivative instruments ,546 current assets ,220 Total current assets ,549 Property & equipment - oil & natural gas properties, succesful efforts method, at cost ,053 Property & equipment - support equipment & facilities, at cost ,225 Property & equipment - other, at cost ,133 Accumulated depreciation, depletion & impairment ,979 net ,432 Restricted investments ,938 Other long-term assets ,545 Total assets ,464 Accounts payable ,941 Revenues payable ,427 Accrued lease operating expense ,439 Accrued general & expenses ,412 Accrued capital expenditures ,854 Accrued interest payable ,309 Asset retirement obligation - current Accrued ad valorem taxes Other accrued liabilities ,108 Accrued liabilities ,233 Total current liabilities ,601 Successor credit facility ,000 Total debt ,000 Long-term debt ,000 Asset retirement obligations ,460 Long-term derivative instruments ,470 Total liabilities ,531 Successor warrants ,788 Successor common stock Successor additional paid-in capital ,856 Successor accumulated earnings (deficit) ,286 /partners equity ,933 1 Successor 1. Amplify Energy Corp common unit. 2. Amplify Energy Corp general partner unit. 3. Amplify Energy Corp subordinated unit. 1. Amplify Energy Corp common unit. 2. Amplify Energy Corp general partner unit. 3. Amplify Energy Corp subordinated unit. ANDIAMO CORP Acquisition Development On Mar. 13, 2018, Co. together with its wholly-owned subsidiary Utopya Innovations Inc. signed a Letter of Intent to acquire a telecom holding company CLEC Holding, Inc. in an all-stock transaction, as part of a strategic plan for growth and diversification. Terms of the transaction were not disclosed. ANTARES PHARMA INC. Product sales ,695,000 40,318,000 27,533,000 Development revenue 10,095,000 10,235,000 8,892,000 Licensing revenue.... 1,076, ,000 7,242,000 Royalties ,649,000 1,503,000 1,991,000 Total revenue ,515,000 52,222,000 45,658,000 Cost of product sales ,317,000 23,909,000 12,925,000 Cost of development revenue ,149,000 4,908,000 6,533,000 Total cost of revenue ,466,000 28,817,000 19,458,000 Gross profit ,049,000 23,405,000 26,200,000 development expenses ,147,000 21,127,000 19,731,000 Selling, general & expenses ,353,000 26,395,000 26,931,000 expenses ,500,000 47,522,000 46,662,000 Operating income (loss) (16,451,000) (24,117,000) (20,462,000) Gain on sale of assets , Interest expense ,423, (expense), net ,000 (122,000) (22,000) (expense) (292,000) (122,000) (22,000) before income taxes - U.S (16,762,000) (24,229,000) (21,831,000) before income taxes - Switzerland ,000 10,000 1,347,000 before income taxes.. (16,743,000) (24,239,000) (20,484,000) Income tax provision (benefit) , , (16,743,000) (24,339,000) (20,659,000) - basic ,054, ,992, ,594,079 - diluted ,054, ,992, ,594,079 outstanding ,674, ,167, ,848,512 per share - basic..... $(0.11) $(0.16) $(0.14) per share - diluted.... $(0.11) $(0.16) $(0.14)

5 March 20, 2018 MERGENT OTC UNLISTED NEWS Number of beneficiary , , ,100 Foreign currency translation adjustments (22,484) 13,901 1 Reclassified to conform with presentation; 2 As of March 1, 2018; 3 As of March 1, ; 4 As of March 1, 2016; 5 Approximately Cash & cash equivalents ,562,000 27,715,000 Short term investments ,993, Accounts receivable ,878,000 9,073,000 Raw material , ,000 Work in process ,223,000 2,429,000 Finished goods ,934,000 2,755,000 Inventories ,275,000 5,327,000 Deferred costs ,000 1,773,000 current assets ,323,000 1,376,000 Total current assets ,536,000 45,264,000 Furniture, fixtures & office equipment ,258,000 2,234,000 Production molds & equipment ,322,000 10,582,000 Molds & tooling in process ,023,000 10,150,000 depreciation ,445,000 5,099,000 Equipment, molds, furniture & fixtures, net ,158,000 17,867,000 Patent rights, net ,401,000 2,045,000 Goodwill ,095,000 1,095,000 Other assets ,000 54,000 Total assets ,338,000 66,325,000 Accounts payable ,957,000 7,885,000 Accrued employee compensation & benefits ,470,000 2,703,000 OTREXUP - product sales allowances ,140,000 1,484,000 Other liabilities ,372,000 1,686,000 Deferred revenue ,794,000 6,149,000 Total current liabilities ,733,000 19,907,000 Long-term debt ,858, Deferred revenue - long term ,000 1,200,000 Total liabilities ,791,000 21,107,000 Common stock ,567,000 1,552,000 capital ,965, ,826,000 (accumulated deficit) (270,285,000) (253,445,000) (loss) (700,000) (715,000) equity (deficit) ,547,000 45,218,000 1 Reclassified to conform with presentation 1. Antares Pharma Inc. common. 1. Antares Pharma Inc. common. ANTHERA PHARMACEUTICALS INC 2015 License revenue ,000 2,562,000 Collaborative revenue , ,000 Total revenues ,000 3,185,000 development expenses ,594,000 46,512,000 33,498,000 expenses ,938,000 11,071,000 7,568,000 Research expense (award) (100,000) (261,000) (2,638,000) expenses ,432,000 57,322,000 38,428,000 operations (36,432,000) (57,177,000) (35,243,000) (expense) (85,000) (90,000) 23,000 Fair value of warrant liability in excess of proceeds from financing (600,000) Change in fair value of warrant liability ,243,000 1,744, (expense) ,558,000 1,654,000 23, (26,874,000) (55,523,000) (35,220,000) Deemed dividends preferred stock ,503,000 10,914, to applicable to common stockholders (29,377,000) (66,437,000) (35,220,000) - basic ,278, ,163,784 4,453,905 - diluted ,278, ,163,784 4,453,905 outstanding ,854, ,745, ,000,505 per share - basic..... $(2.86) 1 $(12.88) $(7.92) per share - diluted.... $(2.86) 1 $(12.88) $(7.92) Number of preferred Adjusted for 1-for-8 stock split, May 1, ; 2 Shares increased due to the effect shares issued for cash and license fee, upon release of restricted stock, equity purchase agreement, atthe-market equity program, exercise of stock options and ESOP Cash & cash equivalents ,196,000 20,843,000 current assets ,000 1,865,000 Total current assets ,191,000 22,708,000 Laboratory equipment ,877,000 2,013,000 Computer & software , ,000 Office furniture & fixture , ,000 Leasehold improvements , ,000 Total property & equipment ,338,000 2,474,000 depreciation & amortization ,856,000 1,711,000 net , ,000 Total assets ,673,000 23,471,000 Accounts payable ,832,000 4,782,000 Accrued clinical expenses ,785,000 3,884,000 Accrued payroll ,066,000 1,845,000 Other accrued liabilities , ,000 Total current liabilities ,711,000 10,624,000 Warrant liability ,457, Total liabilities ,168,000 10,624,000 Contingently redeemable series X convertible preferred stock ,000 Series X convertible preferred stock ,000 8,614,000 Common stock ,000 6,000 capital ,586, ,404,000 (accumulated deficit) (434,428,000) (407,554,000) equity (deficit) (5,495,000) 12,470,000 1 Reclassified to conform with presentation 1. Anthera Pharmaceuticals Inc series X convertible preferred. 2. Anthera Pharmaceuticals Inc common. 1. Anthera Pharmaceuticals Inc series X convertible preferred. 2. Anthera Pharmaceuticals Inc common. ANTHERA PHARMACEUTICALS INC Auditor s Report Auditor s Report The following is an excerpt from the Report of the Independent Auditors, BDO USA, LLP, as it appeared in Co. s 10K report: "Opinion We have audited the accompanying consolidated balance sheets of Anthera Pharmaceuticals, Inc. (the "Company") as of December 31, and 2016, the related consolidated statements of operations, Series X Convertible Preferred Stock and Stockholders Equity (Deficit), and cash flows for each of the three years in the period ended December 31, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, and 2016, and the results of their operations and their cash flows for each of the three years in the period ended December 31,, in conformity with accounting principles generally accepted in the United States of America. Going concern uncertainty The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty." APPLIANCE RECYCLING CENTERS OF AMERICA New Accountant On Mar. 5, 2018, Co. dismissed Anton & Chia, LLP and engaged Weinberg & Company, P.A. as its new independent public accounting firm. APRICUS BIOSCIENCES INC 2015 License fee revenue ,600,000 Royalty revenue ,000 Product sales ,000 Total revenue ,839,000 Cost of goods sold ,000 Gross profit (loss) ,917,000 development expense. 3,463,000 5,880,000 14,649,000 expense ,210,000 7,778,000 10,516,000 Loss on disposal of assets (2,000) (14,000) (102,000) expense ,675,000 13,672,000 25,267,000 before other income (expense) (10,675,000) (13,672,000) (21,350,000) Interest expense, net , , ,000 Change in fair value of warrant liability (646,000) 7,479,000 3,236,000

6 222 MERGENT OTC UNLISTED NEWS March 20, 2018 Gain (loss) on extinguishment of debt (422,000) Other financing expenses , (expense), net ,000 (22,000) (64,000) (expense) (1,074,000) 6,013,000 2,327,000 Income tax expense operations (11,749,000) (7,659,000) (19,023,000) operations ,070, , ,000 (7,433,000) (19,023,000) shares outstanding-basic ,892,000 6,516, ,972,858 shares outstanding-diluted... 11,892,000 6,516, ,972,858 outstanding ,217,231 7,733,205 per share from operations - basic.... $(0.99) $(1.18) 2 5,041,448 2 $(3.80) per share from operations - basic.... $1.01 $ per share - basic..... $0.02 $(1.15) 2 $(3.80) per share from operations - diluted $(0.99) $(1.18) 2 $(3.80) per share from operations - diluted $1.01 $ per share - diluted.... $0.02 $(1.15) 2 $(3.80) Number of beneficiary Restated to reflect the sale of the assets and rights related to Vitaros products as operations; 2 Adjusted for 1-for-10 stock split, October 24, 2016; 3 Shares increased due to the effect of issuance of common stock and warrants; 4 As of February 26, 2018; 5 As of March 3, 2016; 6 Approximately Cash ,331,000 2,087,000 current assets , ,000 Current assets of operations ,370,000 Total current assets ,592,000 3,634,000 Leasehold improvements ,000 20,000 Machinery & equipment , ,000 Capital lease equipment ,000 76,000 Computer software , ,000 Furniture & fixtures ,000 25,000 Total property & equipment, gross , ,000 depreciation & amortization , ,000 net , ,000 Other long term assets ,000 60,000 Noncurrent assets of operations ,000 Total assets ,706,000 4,700,000 Accounts payable , ,000 Professional fees , ,000 Outside research & development services , ,000 Deferred compensation ,000 Other accrued expenses , ,000 Accrued expenses ,000 1,333,000 Accrued compensation , ,000 Deferred revenue , Notes payable, net ,650,000 Current liabilities of operations ,934,000 Total current liabilities ,583,000 11,294,000 Warrant liabilities , ,000 Deferred rent ,000 76,000 Security deposit , Total liabilities ,335,000 12,216,000 Common stock ,000 8,000 Additional paid-in-capital ,343, ,784,000 (accumulated deficit) (315,987,000) (316,308,000) equity ,371,000 (7,516,000) 1 Restated to reflect the sale of the assets and rights related to Vitaros products as operations 1. Apricus Biosciences Inc common. 1. Apricus Biosciences Inc common. APRICUS BIOSCIENCES INC Auditor s Report Auditor s Report The following is an excerpt from the Report of Independent Auditors, BDO USA, LLP, as it appeared in the Form 10-K: "Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of Apricus Biosciences, Inc. (the "Company") and subsidiaries as of December 31, and 2016, the related consolidated statements of operations, changes in stockholders equity (deficit), and cash flows for each of the two years in the period ended December 31,, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company and subsidiaries at December 31, and 2016, and the results of its operations and its cash flows for each of the two years in the period ended December 31,, in conformity with accounting principles generally accepted in the United States of America. Going Concern Uncertainty The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations that raise substantial doubt about its ability to continue as a going concern. Management s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty." ARO LIQUIDATION INC Bankruptcy Proceedings On Mar. 13, 2018, multiple parties including the SEC, the Louisiana Department of Revenue and the U.S. Trustee assigned to Co. s case - filed with the U.S. Bankruptcy Court separate objections to Co. s Revised Third Amended Joint Plan of Reorganization. The Trustee asserts, "The United States Trustee objects to the Third Amended Joint Plan because it contains broad non-debtor third-party releases and an exculpation provision. The plan proponents fail to meet their burden of proof with respect to whether this Court has subject matter jurisdiction to impose these releases and whether the Plan can be confirmed under the standards set forth by the Second Circuit in Metromedia." ASSEMBLY BIOSCIENCES INC Collaboration revenue ,018, development expenses ,225,021 33,092,977 18,357,937 expenses ,020,607 12,185,484 11,297,693 expenses ,245,628 45,278,461 29,655,630 operations (52,226,878) (45,278,461) (29,655,630) Interest & other income ,209 1,539,088 1,228,830 Realized gain (loss) from marketable securities (615,128) (1,139,861) (27,033) (expense) , ,227 1,201,797 before income taxes.. (51,858,797) (44,879,234) (28,453,833) Income tax expense (benefit) (9,050,249) (617,672) (42,808,548) (44,261,562) (28,453,833) - basic ,750,380 17,226,245 15,702,646 - diluted ,750,380 17,226,245 15,702,646 outstanding ,137,974 17,246,754 17,225,662 per share - basic..... $(2.41) $(2.57) $(1.81) per share - diluted.... $(2.41) $(2.57) $(1.81) Number of employees Reclassified to conform with 2016 presentation; 2 As of February 24, ; 3 As of March 7, 2016; 4 As of February 22, 2018 Cash & cash equivalents ,033,209 28,575,085 Marketable securities, at fair value ,914,482 24,388,403 Accounts receivable from collaboration ,273, current assets , ,176 Total current assets ,118,512 53,574,664 Marketable securities ,347,213 2,435,753 Computer hardware & software ,968 86,228 Lab equipment , ,735 Office equipment ,354 1,109 Leasehold improvements ,700 68,213 Tptal property, plant & equipment ,273, ,285 depreciation & amortization , ,598 Property, plant & equipment, net , ,687 Security deposits , ,366 Intangible assets ,000,000 29,000,000 Goodwill ,638,136 12,638,136 Total long-term assets ,184,933 44,543,942 Total assets ,303,445 98,118,606 Accounts payable ,123,939 2,368,131 Accrued salaries, bonuses & employee benefits ,518,128 2,884,000 Accrued severance expenses ,737 Accrued research & development expenses , ,674 Accrued general & expenses , ,412 Accrued expenses ,139,000 4,752,823

7 March 20, 2018 MERGENT OTC UNLISTED NEWS 223 Deferred revenue - short-term ,229, Total current liabilities ,492,166 7,120,954 Deferred tax liabilities ,135,802 11,119,651 Deferred revenue - long-term ,555, Total long-term liabilities ,691,510 11,119,651 Total liabilities ,183,676 18,240,605 Common stock ,138 17,247 capital ,528, ,688,990 (loss) (392,391) (600,769) (accumulated deficit) (251,036,015) (208,227,467) equity (deficiency) ,119,769 79,878,001 diluted Reclassified to conform with presentation Earnings (loss) per share- operations - 1. Assembly Biosciences Inc series A non-voting convertible diluted preferred. per share - diluted.... $(0.91) $(2.16) 2. Assembly Biosciences Inc common Assembly Biosciences Inc series A non-voting convertible Number of part time preferred Assembly Biosciences Inc common. 7 6 ATOSSA GENETICS INC 2015 Product sales ,758 Total revenue ,758 Cost of revenue - product sales ,411 Total cost of revenue ,411 Gross profit (loss) from operations (130,653) Selling expenses ,421,409 development expenses ,328, ,427 2,359,593 expenses ,859,369 6,479,193 8,846,963 Impairment of intangible assets , , expenses ,649,171 7,968,590 12,627,965 Operating income (loss) (7,649,171) (7,968,590) (12,758,618) Change in fair value of common stock warrants , Warrant financing expense , ,599, before income taxes.. (8,122,581) (6,368,885) (12,758,187) operations (12,758,187) operations (3,002,136).... (8,122,581) (6,368,885) (15,760,323) Deemed dividends Series A Preferred Stock ,568, applicable to common stockholders (10,690,713) (6,368,885)... - basic ,697,273 2,947, ,895,168 - diluted ,697,273 2,947, ,895,168 outstanding ,822,741 3,786, ,177,150 Earnings (loss) per share- operations - basic $(6.75) Earnings (loss) per share- operations - basic $(1.50) per share - basic..... $(0.91) $(2.16) 3 $(8.25) Earnings (loss) per share- operations - 3 $(6.75) Number of beneficiary , ,637 3 $(1.50) 3 $(8.25) ,100 1 Restated to reflect correction of inadvertent errors in the weighted average and loss per common share; 2 Including loss on disposal - operations: $670,943; 3 Adjusted for 1-for-15 stock split, August 26, 2016; 4 Shares increased due to the issuance of common shares and warrants; 5 As of March 30, 2016; 6 Approximately; 7 As of February 28, 2018; 8 As of March 1, ; 9 As of March 28, 2016 Cash & cash equivalents ,217,469 3,027,962 Restricted cash ,000 55,000 Prepaid insurances , ,333 Tradeshows ,000 Professional services , Retainer & security deposits ,218 14,218 Other prepaid expenses ,882 16,050 Prepaid expenses , ,601 development tax rebate receivable , Other current assets , Total current assets ,898,034 3,254,563 Furniture & equipment , ,528 depreciation , ,409 Furniture & equipment, net ,467 55,119 Intangible assets, net , ,440 Other assets , ,250 Total assets ,164,094 4,144,372 Accounts payable , ,320 Accrued expenses ,105 16,964 Accrued bonus payable , ,337 Accrued vacation ,861 94,514 Accrued payroll liabilities ,006 66,048 Other current liabilities ,534 6,083 Total current liabilities ,225,407 1,047,266 Total liabilities ,047,266 Common stock ,342 56,804 capital ,887,674 60,344,050 (accumulated deficit) (65,426,329) (57,303,748) equity (deficit) ,938,687 3,097,106 1 Restated to reflect correction of inadvertent errors in the weighted average and loss per common share 1. Atossa Genetics Inc common. 1. Atossa Genetics Inc common. AVEO PHARMACEUTICALS INC Collaboration & licensing revenue.... 7,579,000 2,515,000 19,024,000 development expenses ,179,000 23,703,000 12,875,000 expenses ,138,000 8,205,000 10,217,000 Settlement costs ,073, ,000,000 Restructuring & lease exit ,358,000 expenses ,390,000 31,908,000 31,450,000 operations (28,811,000) (29,393,000) (12,426,000) Interest expense, net ,373,000 1,949,000 2,286,000 Change in fair value of warrant liability (33,740,000) 4,751, (expense) (195,000) (289,000) (expense), net (36,113,000) 2,607,000 (2,575,000) before provision for income taxes..... (64,924,000) (26,786,000) (15,001,000) Provision (benefit) for income taxes , , (65,025,000) (26,887,000) (15,001,000) - basic ,930,000 69,268,000 55,701,000 - diluted ,930,000 69,268,000 55,701,000 outstanding ,325, ,862,946 58,181,715 per share - basic..... $(0.61) $(0.39) $(0.27) per share - diluted.... $(0.61) $(0.39) $(0.27) Reclassified to conform with presentation; 2 Shares increased due to the effect of issuance for common stock and warrants in private placement and to related parties, and exercise of stock options; 3 Approximately; 4 As of March 8, 2018; 5 As of March 17, ; 6 As of March 9, 2016 Cash & cash equivalents ,949,000 15,096,000 Marketable securities ,576,000 8,252,000 Accounts receivable ,000 1,027,000 Insurance recovery ,000, Clinical trial retainers ,027,000 1,702,000 Other prepaid expenses & other current assets , ,000 Total current assets ,183,000 26,315,000 Clinical trial retainers ,000